Delivery Order SPE2DE21D0005-SPE2D625F0Y02

Award Date 3/4/25
Potential Completion Date 3/6/25
Potential Value $3.4K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Fixed Price with Economic Price Adjustment
Place of Performance
Canton, MA 02021, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
65
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a leading regenerative medicine company. The contract, valued at $4,645.00, is for the supply of PURAPLY MZ 500MG, a regenerative wound care product. Organogenesis is a for-profit organization and a manufacturer of goods. The contract does not utilize any set-aside designations. This delivery order is part of a larger $49.5 million multiple-award Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a regenerative medicine company specializing in advanced wound care, surgical biologics, and tissue regeneration products. The contract, valued at $5,100.00, is for the supply of PURAPLY AM XT 4.91X4.91 medical products. This is not a set-aside contract, indicating Organogenesis competed as a standard commercial vendor. The contract is a fixed-price with economic price...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,118.88 fixed-price delivery order with economic price adjustment to Organogenesis Inc., a leading regenerative medicine company based in Canton, Massachusetts. The order is for PURAPLY AM (2x2) 4 SQ CM, an advanced wound care product. This order is part of Organogenesis' broader federal contract vehicles, including a $49.5 million multiple-award Indefinite Delivery Contract with DLA Troop Support Medical for wound care...
This is a $1,118.88 fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a regenerative medicine company, to provide PURAPLY AM wound dressings. The order is part of a larger $49.5 million multiple-award indefinite delivery contract (IDC) that Organogenesis holds with DLA for wound care dressings, discs, and other medical materials through May 2026. Organogenesis also maintains Blanket Purchase Agreements valued up to $7 million...
This $8,500 fixed-price delivery order was awarded to Organogenesis Inc., a regenerative medicine company, by the Defense Logistics Agency (DLA) Troop Support Medical on September 11, 2024. The order is for the supply of PURAPLY AM XT, a wound care product, with an ultimate completion date of September 16, 2024. Organogenesis is a key supplier of advanced wound care and surgical biologics products to the U.S. government, primarily serving the Department of Defense and Department of Veterans...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a leading regenerative medicine company specializing in advanced wound care and surgical biologics products. The contract, valued at $8,150.00, is for the delivery of PURAPLY MZ 500MG, a wound care product. Organogenesis holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies, including a $25 million single-award Indefinite Delivery Contract...
This federal contract award was issued by the Medical Supply Chain, a component of the Department of Defense's Defense Logistics Agency (DLA), to Organogenesis Inc., a for-profit manufacturer of regenerative medical products. The $1,140 fixed-price with economic price adjustment delivery order is for the supply of PURAPLY MZ 500MG, a wound care product. This award is not a set-aside contract. Organogenesis is a key supplier of advanced wound care, surgical biologics, and tissue regeneration...
The Defense Logistics Agency Troop Support Medical awarded a $1,118.88 fixed-price delivery order with economic price adjustment to Organogenesis Inc., a leading regenerative medicine company. The order is for PURAPLY AM (2x2) 4 sq cm, a wound care dressing product. Organogenesis Inc. has provided a variety of surgical implants, wound care dressings, and tissue regeneration products to federal agencies like the Department of Veterans Affairs and the Defense Logistics Agency through multiple...
The U.S. Defense Logistics Agency Troop Support Medical has awarded Organogenesis Inc., a leading regenerative medicine company, a $1,118.88 fixed-price delivery order contract for PURAPLY AM (2x2) 4 SQ CM wound dressings. This is not a set-aside contract. Organogenesis is a for-profit manufacturer that has been awarded numerous prime federal contracts to provide wound care products, surgical implants, and tissue regeneration solutions to government agencies, including the Department of...
The U.S. Department of Defense's Medical Supply Chain (Defense Logistics Agency Troop Support Medical) has awarded Organogenesis Inc. a $8,500.00 fixed-price delivery order contract (SPE2DE21D0005|SPE2D624F9CS2) for the supply of PURAPLY AM XT 4.91x4.91 medical products. This delivery order is part of Organogenesis' existing $49.5 million multiple-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency for wound care dressings, discs, and medical materials. Organogenesis is...
  • SPE2DE21D0005
    Indefinite Delivery Contract
  • SPE2DE21D0005-SPE2D625F0Y02
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a for-profit manufacturer of regenerative medical products headquartered in Canton, Massachusetts. The contract, valued at $3,420.00, is for the supply of PURAPLY MZ 500MG, a wound care product. The contract is a fixed-price with economic price adjustment and has a period of performance through March 6, 2025. This award is not associated with a set-aside designation, indicating Organogenesis competes as a standard commercial vendor. Organogenesis holds several significant federal Indefinite Delivery Vehicles (IDVs) with the Department of Veterans Affairs (VA) and DLA, demonstrating its strategic position in government medical procurement for regenerative medicine products supporting advanced wound care and tissue regeneration treatments for military personnel and veterans.

Generated 6/3/25, 9:45 AM